<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JIC</journal-id>
<journal-id journal-id-type="hwp">spjic</journal-id>
<journal-id journal-id-type="nlm-ta">J Intensive Care Med</journal-id>
<journal-title>Journal of Intensive Care Medicine</journal-title>
<issn pub-type="ppub">0885-0666</issn>
<issn pub-type="epub">1525-1489</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0885066612457331</article-id>
<article-id pub-id-type="publisher-id">10.1177_0885066612457331</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Agony With Ecstasy</article-title>
<subtitle>Lessons From a Recent Rave</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hoo</surname>
<given-names>Guy W. Soo</given-names>
</name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff1-0885066612457331">1</xref>
<xref ref-type="corresp" rid="corresp1-0885066612457331"/>
</contrib>
</contrib-group>
<aff id="aff1-0885066612457331">
<label>1</label>Pulmonary and Critical Care (111Q), West Los Angeles VA Healthcare Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA</aff>
<author-notes>
<corresp id="corresp1-0885066612457331">Guy W. Soo Hoo, Pulmonary and Critical Care (111Q), West Los Angeles VA Healthcare Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Email: <email>guy.soohoo@va.gov</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>259</fpage>
<lpage>261</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<kwd-group>
<kwd>ecstasy</kwd>
<kwd>amphetamine</kwd>
<kwd>methamphetamine</kwd>
<kwd>drug intoxication</kwd>
<kwd>hyperthermia</kwd>
<kwd>rhabdomyolysis</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>July/August 2013</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>The compound 3,4-methylenedioxymethamphetamine (MDMA), more commonly known as “Ecstasy”, is a well recognized but often an underappreciated drug of abuse. It is a synthetic derivative of amphetamine intended for use as an appetite suppressant when created in 1912. This never materialized and use was dormant until the 1970s, when reports surfaced on its use in psychoanalysis and as a recreational drug.<sup>
<xref ref-type="bibr" rid="bibr1-0885066612457331">1</xref>
</sup> While similar to amphetamine, it has a methylenedioxy ring substitution and resembles the hallucinogen mescaline. Its abuse potential led to its classification as a scheduled I hallucinogen in 1985, by the Food and Drug Administration. It is no longer used for medicinal purposes, except in an investigational setting.<sup>
<xref ref-type="bibr" rid="bibr2-0885066612457331">2</xref>
</sup> Its main effects of mood enhancement and euphoria have made it a favorite in dance clubs and “rave” parties. Reports place it just behind amphetamine compounds and ahead of cocaine in terms of its use in adults, with an estimated consumption of as many as 2 millions tablets weekly and over 28 million worldwide users<sup><xref ref-type="bibr" rid="bibr3-0885066612457331">3</xref>,<xref ref-type="bibr" rid="bibr4-0885066612457331">4</xref>
</sup> (<xref ref-type="fig" rid="fig1-0885066612457331">Figure 1</xref>). There are recent reports of its resurgent use in Europe and in the United States.<sup>
<xref ref-type="bibr" rid="bibr5-0885066612457331">5</xref>
</sup>
</p>
<fig id="fig1-0885066612457331" position="float">
<label>Figure 1.</label>
<caption>
<p>Annual prevalence of illicit drug use among the population aged 15 to 64 years, in 2008 to 2010. Adapted from the World Drug Report 2012.<sup><xref ref-type="bibr" rid="bibr4-0885066612457331">4</xref></sup>
</p>
</caption>
<graphic xlink:href="10.1177_0885066612457331-fig1.tif"/>
</fig>
<p>It is important to recognize that while “Ecstasy” usually refers to MDMA, there are several other street names for the compound including X, XTC, and Adam as well as a number of related compounds that differ chemically but have similar effects. There are over a dozen of these “Ecstasy”-related compounds, with 3,4-methylenedioxyethamphetamine (MDEA or “Eve”) and 3,4-methylenedioxyamphetamine (MDA or “ice”) the most common.<sup>
<xref ref-type="bibr" rid="bibr6-0885066612457331">6</xref>
</sup> While typically produced as a tablet, “Ecstasy” can also be found in capsule or powder form, and in addition to oral ingestion, other routes of administration include the inhalational, intranasal, intravenous, and subcutaneous routes. There is also no uniformity as to the amount of MDMA in any tablet but it is usually in the 30- to 150-mg range and often mixed with its sister agents (above) as well as other compounds such as amphetamine, methamphetamine, ketamine, caffeine, and acetaminophen.<sup>
<xref ref-type="bibr" rid="bibr7-0885066612457331">7</xref>
<xref ref-type="bibr" rid="bibr8-0885066612457331"/>–<xref ref-type="bibr" rid="bibr9-0885066612457331">9</xref>
</sup> Some drugs sold as “Ecstasy” may not contain any of the named agent.<sup>
<xref ref-type="bibr" rid="bibr6-0885066612457331">6</xref>
</sup> As might be expected, ingestion results in a broad range of both desired and undesired effects. These varying doses and added ingredients also make it difficult to predict its toxicity, and ingestion of an excessive dose may be unintended. Estimates of death from first-time use range widely from 1 (0.05%) of 2000 to 1 (0.002%) of 50 000.<sup>
<xref ref-type="bibr" rid="bibr10-0885066612457331">10</xref>
</sup> The typical death involved a young caucasian male and occurred predominantly on a weekend day (Saturday or Sunday).<sup>
<xref ref-type="bibr" rid="bibr11-0885066612457331">11</xref>
</sup>
</p>
<p>The heterogeneity of the drug dose and tablet composition understandably results in sporadic presentations of severe toxicity and it often requires years to accumulate any substantial number of cases.<sup>
<xref ref-type="bibr" rid="bibr2-0885066612457331">2</xref>,<xref ref-type="bibr" rid="bibr12-0885066612457331">12</xref>
<xref ref-type="bibr" rid="bibr13-0885066612457331"/>–<xref ref-type="bibr" rid="bibr14-0885066612457331">14</xref>
</sup> Most reports involve a single case, rarely more than a handful of cases come to the attention of any one provider or group. Therefore, the report by Armenian et al provides a unique perspective on a fairly large number of cases associated with one event.<sup>
<xref ref-type="bibr" rid="bibr15-0885066612457331">15</xref>
</sup> The authors were able to document the presence of MDMA in capsules available at the event, in what would be considered high-quality doses (&gt;80 mg and &gt;80% MDMA), and the presence of the agent in serum and urine toxicology. The drug was widely available at the event, with &gt;800 pills confiscated by authorities. As would be expected, only those with the most severe toxicity came to attention and there were two deaths. There were an estimated 16 000 attendees, and while the numbers with MDMA use cannot be determined, if only 4000 used the drug, the mortality rate would fall within the past reported ranges.</p>
<p>Their series of 12 cases provide additional insight into severe toxicity and can be used as a guide for future cases. Past reports of severe toxicity have documented a wide array of complications including sudden death, cardiac tachyarrhythmias, pneumothorax, cerebral infarction, hyponatremia and cerebral edema, hepatic failure, and serotonin syndrome.<sup>
<xref ref-type="bibr" rid="bibr2-0885066612457331">2</xref>,<xref ref-type="bibr" rid="bibr6-0885066612457331">6</xref>,<xref ref-type="bibr" rid="bibr12-0885066612457331">12</xref>,<xref ref-type="bibr" rid="bibr14-0885066612457331">14</xref>,<xref ref-type="bibr" rid="bibr16-0885066612457331">16</xref>
</sup> Hyperthermia, rhabdomyolysis, and acute kidney injury have also been prominently highlighted as part of the constellation of severe morbidity associated with MDMA.<sup>
<xref ref-type="bibr" rid="bibr17-0885066612457331">17</xref>
<xref ref-type="bibr" rid="bibr18-0885066612457331"/>
<xref ref-type="bibr" rid="bibr19-0885066612457331"/>–<xref ref-type="bibr" rid="bibr20-0885066612457331">20</xref>
</sup> These generally reflect sporadic cases of toxicity so there is never an opportunity to appreciate what may occur with exposure in a large cohort of patients as in this report.</p>
<p>The authors were able to separate the dozen patients into two groups, one with severe morbidity including two deaths and those who recovered without much associated morbidity. The differences between the groups are striking and contribute to a profile that can be characterized as extreme hyperthermia and hypotension, with associated seizures, rhabdomyolysis, acute kidney injury, and associated metabolic and electrolyte disturbances. Multiorgan system dysfunction ensues and includes acute lung injury, acute respiratory distress syndrome (ARDS), hepatic injury, disseminated intravascular coagulation, and cardiac ischemia. The complexity of systemic toxicity makes it difficult to determine the exact sequence of events, but in a crowded environment with high ambient temperatures, hyperthermia is the likely inciting factor in the cascade of events leading to a hyperthermic crisis.</p>
<p>It is important to recognize that while severe toxicity is usually associated with ingestion of large amounts of the drug, severe toxicity can also occur after typical recreational doses of MDMA or may not occur even with high MDMA levels.<sup>
<xref ref-type="bibr" rid="bibr14-0885066612457331">14</xref>,<xref ref-type="bibr" rid="bibr21-0885066612457331">21</xref>
</sup> There is a nonlinear aspect of MDMA pharmacokinetics in which small additional doses of drug can result in markedly elevated plasma levels.<sup>
<xref ref-type="bibr" rid="bibr22-0885066612457331">22</xref>
</sup> It is well recognized that MDMA induces a serotonin syndrome which includes increased muscle tone and rigidity as part of the constellation of symptoms. It becomes apparent that hyperthermia can escalate because of external factors such as the warm, crowded environment of a “rave” party, in which dancing further promotes heat generation.<sup>
<xref ref-type="bibr" rid="bibr23-0885066612457331">23</xref>,<xref ref-type="bibr" rid="bibr24-0885066612457331">24</xref>
</sup> Participants often ignore symptoms of thirst and fatigue to continue dancing, which predisposes to dehydration and exertional hyperthermia, with muscle injury causing rhabdomyolysis, all factors contribute to acute kidney injury and multiorgan system involvement. Seizures also add to muscle injury and hyperthermia. This clinical presentation is similar to that seen in patients with severe heat stroke or malignant hyperthermia, and treatment of severe MDMA toxicity is patterned after the treatment of those conditions which include dantrolene.</p>
<p>Extreme hyperthermia in MDMA toxicity defined as temperatures &gt;42°C have been identified as a threshold that presages severe morbidity and mortality.<sup>
<xref ref-type="bibr" rid="bibr25-0885066612457331">25</xref>
</sup> Temperatures &lt;40°C seem to represent a threshold in which recovery is generally expected. This is borne out in this series where the average peak temperature in those with severe toxicity was 41.6°C and those who survived had an average temperature of 39.3°C. The group with more severe toxicity also had higher levels of muscle injury, hypoxemia, worsening renal function, acidosis, hyperkalemia, and tachycardia. When analyzing the treatment in these groups, the importance of prompt treatment of the hyperthermia becomes apparent. Cooling involved a wide range of cooling measures including dantrolene; and in comparing the time needed to reach 38.9°C, the time was almost twice as long in those with severe morbidity (based on my calculations of 3.37 hours vs 1.75 hours). This underscores the importance of aggressive cooling measures which is becoming more widespread as a treatment modality, given the experience with postcardiac arrest hypothermia. It is acknowledged that such analysis is tempered by its retrospective nature and the time to a goal temperature is as much a function of the amount of cooling required (temperature reduction) as the cooling method. Only external cooling devices were used, but there is increasing availability of intravascular devices which are more efficient in temperature reduction. It follows that the more time spent &lt;39°C can only minimize the adverse of hyperthermia and end organ dysfunction. Cooling measures along with supportive care remain the cornerstones of therapy.</p>
<p>In summary, this report provides a little better understanding of MDMA toxicity and its treatment. The relatively large number of patients provides an opportunity to better define the syndrome of severe toxicity. In this series, toxicity was exacerbated by a combination of several factors including the availability of high-grade MDMA in a crowded, extremely warm venue. Rave parties are never general public knowledge, but recognition of hyperthermic crisis in a young person should trigger suspicion for MDMA ingestion and be an alert for additional cases as well as the need for prompt attention to treatment. Cooling measures may provide the key to minimizing excess morbidity and mortality, with a call to consider aggressive cooling using intravascular cooling devices. There also needs to be further education of MDMA users who incorrectly perceive this as a relatively “safe” drug. This is obviously not the case. Its toll of physical injury, cognitive impairment, and death is almost exclusively in adult users younger than 35 years, and this truly represents the tragedy of “Ecstasy”.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0885066612457331">
<label>Declaration of Conflicting Interests</label>
<p>The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0885066612457331">
<label>Funding</label>
<p>The author received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0885066612457331">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rochester</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kirchner</surname>
<given-names>JT</given-names>
</name>
</person-group>. <article-title>Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology</article-title>. <source>J Am Board Fam Pract</source>. <year>1999</year>;<volume>12</volume>(<issue>2</issue>):<fpage>137</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr2-0885066612457331">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalant</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs</article-title>. <source>CMAJ</source>. <year>2001</year>;<volume>165</volume>:<fpage>917</fpage>–<lpage>928</lpage>.</citation>
</ref>
<ref id="bibr3-0885066612457331">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Elston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Garside</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>The harmful health effects of recreational ecstasy: a systematic review of observational evidence</article-title>. <source>Health Technol Assess</source>. <year>2009</year>;<volume>13</volume>:<fpage>iii</fpage>–<lpage>xii</lpage>, <fpage>1</fpage>.</citation>
</ref>
<ref id="bibr4-0885066612457331">
<label>4</label>
<citation citation-type="web">
<collab collab-type="author">United Nations Office of Drug Control.</collab> <article-title>World Drug Report 2012. Health Technol Assess. 2012</article-title>. <comment>Electronic Citation</comment>; <ext-link ext-link-type="uri" xlink:href="http://www.unodc.org/unodc/en/data-and-analysis/WDR-2012.html">http://www.unodc.org/unodc/en/data-and-analysis/WDR-2012.html</ext-link>; <comment>Accessed July 1, 2012</comment>.</citation>
</ref>
<ref id="bibr5-0885066612457331">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Parrott</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Ringwalt</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Blazer</surname>
<given-names>DG</given-names>
</name>
</person-group>. <article-title>The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions</article-title>. <source>Am J Addict</source>. <year>2009</year>;<volume>18</volume>:<fpage>452</fpage>–<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr6-0885066612457331">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management</article-title>. <source>Br J Anaesth</source>. <year>2006</year>;<volume>96</volume>(<issue>6</issue>):<fpage>678</fpage>–<lpage>685</lpage>.</citation>
</ref>
<ref id="bibr7-0885066612457331">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parrott</surname>
<given-names>AC</given-names>
</name>
</person-group>. <article-title>Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2004</year>;<volume>173</volume>(<issue>3-4</issue>):<fpage>234</fpage>–<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr8-0885066612457331">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherlock</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Conner</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department</article-title>. <source>J Accid Emerg Med</source>. <year>1999</year>;<volume>16</volume>(<issue>3</issue>):<fpage>194</fpage>–<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr9-0885066612457331">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolff</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Sherlock</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Conner</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Contents of “ecstasy”</article-title>. <source>Lancet</source>. <year>1995</year>;<volume>346</volume>(<issue>8982</issue>):<fpage>1100</fpage>–<lpage>1101</lpage>.</citation>
</ref>
<ref id="bibr10-0885066612457331">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gore</surname>
<given-names>SM</given-names>
</name>
</person-group>. <article-title>Fatal uncertainty: death-rate from use of ecstasy or heroin</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>354</volume>:<fpage>1265</fpage>–<lpage>1266</lpage>.</citation>
</ref>
<ref id="bibr11-0885066612457331">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schifano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Oyefeso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pollard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Corkery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ghodse</surname>
<given-names>AH</given-names>
</name>
</person-group>. <article-title>Review of deaths related to taking ecstasy, England and Wales, 1997-2000</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>326</volume>(<issue>7380</issue>):<fpage>80</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr12-0885066612457331">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dowling</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>McDonough</surname>
<given-names>ET</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Bost</surname>
<given-names>RO</given-names>
</name>
</person-group>. <article-title>‘Eve’ and ‘Ecstasy’. A report of five deaths associated with the use of MDEA and MDMA</article-title>. <source>JAMA</source>. <year>1987</year>;<volume>257</volume>(<issue>12</issue>):<fpage>1615</fpage>–<lpage>1617</lpage>.</citation>
</ref>
<ref id="bibr13-0885066612457331">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greene</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Dargan</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>O'connor</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kerins</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Multiple toxicity from 3,4-methylenedioxymethamphetamine (“ecstasy”)</article-title>. <source>Am J Emerg Med</source>. <year>2003</year>;<volume>21</volume>(<issue>2</issue>):<fpage>121</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr14-0885066612457331">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Jeffreys</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Dawling</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”)</article-title>. <source>Lancet</source>. <year>1992</year>;<volume>340</volume>(<issue>8816</issue>):<fpage>384</fpage>–<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr15-0885066612457331">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armenian</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mamantov</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Tsutaoka</surname>
<given-names>BT</given-names>
</name>
<etal/>
</person-group>. <article-title>Multiple MDMA (Ecstasy) overdoses at a rave event: a case series [published online on May 28, 2012]</article-title>. <source>J Intensive Care Med</source>. <year>2012</year>.</citation>
</ref>
<ref id="bibr16-0885066612457331">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Korey</surname>
<given-names>WS.</given-names>
</name>
</person-group> <article-title>Death by “ecstasy”: the serotonin syndrome?</article-title> <source>Ann Emerg Med</source>. <year>1998</year>;<volume>32</volume>(<issue>3 pt 1</issue>):<fpage>377</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr17-0885066612457331">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fahal</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Sallomi</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Yaqoob</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>GM</given-names>
</name>
</person-group>. <article-title>Acute renal failure after ecstasy</article-title>. <source>BMJ</source>. <year>1992</year>;<volume>305</volume>:<fpage>29</fpage>.</citation>
</ref>
<ref id="bibr18-0885066612457331">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mallick</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bodenham</surname>
<given-names>AR</given-names>
</name>
</person-group>. <article-title>MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C</article-title>. <source>J Accid Emerg Med</source>. <year>1997</year>;<volume>14</volume>(<issue>5</issue>):<fpage>336</fpage>–<lpage>338</lpage>.</citation>
</ref>
<ref id="bibr19-0885066612457331">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Screaton</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Thrasher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sarner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>SL</given-names>
</name>
</person-group>. <article-title>Hyperpyrexia and rhabdomyolysis after MDMA (“ecstasy”) abuse</article-title>. <source>Lancet</source>. <year>1992</year>;<volume>339</volume>(<issue>8794</issue>):<fpage>677</fpage>–<lpage>678</lpage>.</citation>
</ref>
<ref id="bibr20-0885066612457331">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simpson</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Rumack</surname>
<given-names>BH</given-names>
</name>
</person-group>. <article-title>Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology</article-title>. <source>Arch Intern Med</source>. <year>1981</year>;<volume>141</volume>:<fpage>1507</fpage>–<lpage>1509</lpage>.</citation>
</ref>
<ref id="bibr21-0885066612457331">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milroy</surname>
<given-names>CM.</given-names>
</name>
</person-group> <article-title>“Ecstasy” associated deaths: what is a fatal concentration? Analysis of a case series</article-title>. <source>Forensic Sci Med Pathol</source>. <year>2011</year>;<volume>7</volume>(<issue>3</issue>):<fpage>248</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr22-0885066612457331">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la</surname>
<given-names>Torre</given-names>
</name>
<name>
<surname>Farre</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roset</surname>
<given-names>PN</given-names>
</name>
<etal/>
</person-group>. <article-title>Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition</article-title>. <source>Ther Drug Monit</source>. <year>2004</year>;<volume>26</volume>(<issue>2</issue>):<fpage>137</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr23-0885066612457331">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parrott</surname>
<given-names>AC</given-names>
</name>
</person-group>. <article-title>MDMA and temperature: a review of the thermal effects of ‘Ecstasy’ in humans</article-title>. <source>Drug Alcohol Depend</source>. <year>2012</year>;<volume>121</volume>(<issue>1-2</issue>):<fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr24-0885066612457331">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Kiyatkin</surname>
<given-names>EA</given-names>
</name>
</person-group>. <article-title>Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions</article-title>. <source>Eur J Neurosci</source>. <year>2004</year>;<volume>20</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr25-0885066612457331">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grunau</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Wiens</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Brubacher</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review</article-title>. <source>CJEM</source>. <year>2010</year>;<volume>12</volume>(<issue>5</issue>):<fpage>435</fpage>–<lpage>442</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>